Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
- DOI
- 10.1016/s2213-8587(19)30384-5
- Published
- 2020 Jan
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-19-30384-5,
title = {Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.},
author = {Heerspink HJL and Karasik A and Thuresson M and Melzer-Cohen C and Chodick G and Khunti K and Wilding JPH and Garcia Rodriguez LA and Cea-Soriano L and Kohsaka S and Nicolucci A and Lucisano G and Lin FJ and Wang CY and Wittbrodt E and Fenici P and Kosiborod M},
year = {2020},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(19)30384-5},
url = {https://doi.org/10.1016/s2213-8587(19)30384-5}
}RIS
TY - JOUR TI - Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. AU - Heerspink HJL AU - Karasik A AU - Thuresson M AU - Melzer-Cohen C AU - Chodick G AU - Khunti K AU - Wilding JPH AU - Garcia Rodriguez LA AU - Cea-Soriano L AU - Kohsaka S AU - Nicolucci A AU - Lucisano G AU - Lin FJ AU - Wang CY AU - Wittbrodt E AU - Fenici P AU - Kosiborod M PY - 2020 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(19)30384-5 UR - https://doi.org/10.1016/s2213-8587(19)30384-5 ER -
APA
HJL, H., A, K., M, T., C, M., G, C., K, K., JPH, W., LA, G. R., L, C., S, K., A, N., G, L., FJ, L., CY, W., E, W., P, F., & M, K. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(19)30384-5
Source records
- pubmed · retrieved 2026-09-27T16:30:25.091Z